Docentföreläsning: Riktad metabolomik i kliniska prover

  • Datum: –14.30
  • Plats: Biomedicinskt centrum Scheelerummet C6:3 BMC, Husargatan 3
  • Föreläsare: Fil dr, forskare Kumari Ubhayasekhera
  • Webbsida
  • Arrangör: Institutionen för kemi-BMC
  • Kontaktperson: Jonas Bergquist
  • Telefon: 070-9621393
  • Docentföreläsning

Föreläsningen, som är ett lärarprov för den som ansökt om att bli antagen som docent, ska kunna följas av studenter och andra med kunskaper på grundutbildningsnivå inom ämnet, men kan även vara av intresse för en bredare publik. Föreläsningen varar 45 minuter med efterföljande frågestund och diskussion. Föreläsningen kommer att ges på engelska.

Välkomna!

Metabolomics is the systematic identification and quantitation of biologically relevant small molecules in a given biological sample (cell, tissue, or organism). It represents the functional end-point of physiological and pathophysiological processes representing both genetic predisposition and environmental influences. Metabolomics aims to measure a wide range of small molecules in the context of physiological stimuli or disease states. The methodologies for these measurements fall into two distinct groups: untargeted metabolomics, an intended comprehensive analysis of all the measurable analytes in a sample including chemical unknowns, and targeted metabolomics, the measurement of defined groups of chemically characterized and biochemically annotated metabolites. The focus of this lecture is to discuss the methodologies used for targeted metabolomics experiments, and the advantages of this approach. A summary of the procedures for extracting the targeted metabolites (free fatty acids, amino acids, steroids, and oxycholesterols), intermediary pathway metabolites (from tryptophan metabolism, TCA and methionine cycles) will be described. The analytical protocols based on supercritical chromatography and liquid chromatography hyphenated with tandem mass spectrometry will be outlined with several examples of valuable findings from metabolomics-led studies on diabetes, neurodegenerative disorders, and cancer.  The metabolomics research offers ways toward personalized medicine, placing the targeted metabolomics as a platform technology for clinical chemistry.